Venetoclax-Dexamethasone in Relapsed and/or Refractory t(11;14) Amyloidosis | MicrobiomeTrials← Back to trialsNCT05451771
Venetoclax-Dexamethasone in Relapsed and/or Refractory t(11;14) Amyloidosis
RecruitingPHASE1, PHASE2INTERVENTIONAL
Trial Details
Start: 2022-10-26Est. Completion: 2027-09
Enrollment target: 53 participants Locations- The University of Alabama at Birmingham Hospital, Birmingham, Alabama, United States
- Boston Medical Center, Boston, Massachusetts, United States
- Mayo Clinic Rochester, Rochester, Minnesota, United States
- Washington University School of Medicine, St Louis, Missouri, United States
- New York Presbyterian Hospital/Columbia University Irving Medical Center, New York, New York, United States
- Froedtert Hospital & the Medical College of Wisconsin, Milwaukee, Wisconsin, United States
Other microbiome trials you might be interested in
Locally Advanced Cutaneous Squamous Cell Carcinoma of the Head and NeckMelanoma NeoplasmsSmall Cell Bronchial CarcinomasBronchial CarcinomaPleural MesotheliomaHodgkin's LymphomaChronic Lymphocytic LeukemiaFollicular LymphomaMyelomaAL AmyloidosisHepatocarcinomaColorectal CancerEsophageal Squamous Cell CarcinomaHeart CancerCholangiocarcinomaColorectal Adenocarcinoma
Biotherapies are biological (extracted from an organism or living tissue) or biotechnological drugs used in the treatmen…
Angers, France
Est. completion Jun 2028
PGM3 DeficiencyEosinophilic and/or Atopic DermatitisOSMR DeficiencyPrimary Localized Cutaneous AmyloidosisHereditary Alpha-tryptasemia
Background:
\- Allergic inflammation is central to allergy-related diseases and disorders, such as asthma, food allergi…
Bethesda, United States